This study explores the use of faecal calprotectin (FC) measurement as a non-invasive biomarker for diagnosing and managing inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). Elevated FC levels correlate with active disease and can help distinguish IBD from other gastrointestinal conditions like irritable bowel syndrome
